Literature DB >> 18460279

Neurotoxicity of chemotherapeutic and biologic agents in children with cancer.

Kevin C De Braganca1, Roger J Packer.   

Abstract

The sequelae of treatment modalities used to treat childhood cancer are of increasing clinical importance. In children with pediatric malignancies, the full impact of such sequelae may not be apparent until years after treatment. The earlier recognition of these neurotoxicities could possibly alter the course of a treatment or facilitate interventions to improve quality of life.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18460279     DOI： 10.1007/s11910-008-0019-9

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  54 in total

1.  Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children.

Authors:  M N Dufourg; J Landman-Parker; M F Auclerc; C Schmitt; Y Perel; G Michel; P Levy; G Couillault; V Gandemer; M D Tabone; F Demeocq; J P Vannier; T Leblanc; G Leverger; A Baruchel
Journal:  Leukemia       Date:  2006-12-14       Impact factor: 11.528

2.  Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.

Authors:  D H Mahoney; J J Shuster; R Nitschke; S J Lauer; C P Steuber; N Winick; B Camitta
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

3.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy.

Authors:  D Valteau-Couanet; B Fillipini; E Benhamou; J Grill; C Kalifa; D Couanet; J L Habrand; O Hartmann
Journal:  Bone Marrow Transplant       Date:  2005-12       Impact factor: 5.483

5.  Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study.

Authors:  Uri Tabori; Lillian Sung; Juliette Hukin; Normand Laperriere; Bruce Crooks; Anne-Sophie Carret; Mariana Silva; Isaac Odame; Chris Mpofu; Douglas Strother; Beverly Wilson; Yvan Samson; Eric Bouffet
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

6.  Ancestry and pharmacogenetics of antileukemic drug toxicity.

Authors:  Shinji Kishi; Cheng Cheng; Deborah French; Deqing Pei; Soma Das; Edwin H Cook; Nobuko Hijiya; Carmelo Rizzari; Gary L Rosner; Tony Frudakis; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Blood       Date:  2007-01-30       Impact factor: 22.113

7.  Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.

Authors:  Lisa R Bomgaars; Mark Bernstein; Mark Krailo; Richard Kadota; Soma Das; Zhengjia Chen; Peter C Adamson; Susan M Blaney
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

8.  Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.

Authors:  Martin Benesch; Petra Sovinz; Barbara Krammer; Herwig Lackner; Georg Mann; Wolfgang Schwinger; Helmut Gadner; Christian Urban
Journal:  J Pediatr Hematol Oncol       Date:  2007-04       Impact factor: 1.289

Review 9.  Neurological toxicity of ifosfamide.

Authors:  P Nicolao; B Giometto
Journal:  Oncology       Date:  2003       Impact factor: 2.935

Review 10.  Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.

Authors:  J Pelgrims; F De Vos; J Van den Brande; D Schrijvers; A Prové; J B Vermorken
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.